Triad Wealth Partners’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-9
Closed -$211 – 102
2024
Q2
$211 Buy
+9
New +$227 ﹤0.01% 941

Other funds holding ARKG

Triad Wealth Partners's ARKG Position: Q3 2024 in Review

Triad Wealth Partners sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2024, closing a stake of 9 shares — an estimated $211 sold.

Triad Wealth Partners first reported a position in ARKG in Q2 2024 and held it in 1 quarter. The position peaked at $211 in Q2 2024. 240 funds tracked by Wall St. Rank hold ARKG as of Q3 2024.

  • Triad Wealth Partners reported no remaining ARK Genomic Revolution ETF position as of Q3 2024 after selling out during the quarter.
  • Triad Wealth Partners sold 9 ARK Genomic Revolution ETF shares in Q3 2024, an estimated $211.
  • Triad Wealth Partners first reported a position in ARK Genomic Revolution ETF in Q2 2024 and held it in 1 quarter.
  • Triad Wealth Partners's ARK Genomic Revolution ETF position peaked at $211 in Q2 2024.
  • 240 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2024.

Based on Triad Wealth Partners's 13F filing for Q3 2024, filed 21 Oct 2024.